CompletedNot Applicable

Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis

Egypt45 participantsStarted 2023-08-20

Plain-language summary

Background: Smoking reduces the effect of non-surgical periodontal therapy, a host modulation regimen consisting of omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation with low-dose aspirin (ASA) with or without systemic doxycycline has been proposed to improve treatment response. The Aim of the study is to explore the clinical effects of orally administered omega-3 PUFA and ASA with or without systemic doxycycline with periodontal debridement in treatment of smoker individuals with stage III periodontitis.

Who can participate

Age range35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Smoker patients who smoke ≥ 10 cigarettes per day. * Stages III, Grades C periodontitis with at least one site with PD≥6 and CAL ≥5 mm. Exclusion Criteria: * Scaling and root planning in the previous 6 months(that may confound the effect of treatment) * Antimicrobial therapy in the previous 6 months(that may confound the effect of treatment) * Chronic systemic diseases that may have an impact on periodontitis progression (diabetes mellitus). * Systemic diseases that may contraindicate aspirin or doxycycline taking (kidney and liver diseases) * Allergy to doxycycline * Long-term usage of medications that may impair periodontal health * Allergy to fish/seafood

What they're measuring

change in probing depth

Timeframe: baseline (t0) and at 3 (t1) and 6 months (t2)

change in clinical attachment level

Timeframe: baseline (t0) and at 3 (t1) and 6 months (t2)

Trial details

NCT IDNCT07385300

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-22

View on ClinicalTrials.gov More Periodontitis trials